The grant will support the development of an automated, cartridge-based desktop testing instrument for direct-from-blood detection of yeast infections.
The company plans to launch in 2026 a program that will provide labs with scanners free of charge in exchange for volume-based payments for biomarker tests.
The private equity firms invested along with executive Cary Breese, who is slated to become CEO of the clinical lab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback